查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1787906

全球结节性痒疹治疗市场分析及预测（至2032年）：依治疗类型、给药途径、诊断方法、结节性痒疹类型、通路及地区划分

Prurigo Nodularis Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Route of Administration, Diagnosis Method, Type of Nodular Prurigo, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球结节性痒疹治疗市场预计在 2025 年将达到 22 亿美元，到 2032 年将达到 34 亿美元，预测期内的复合年增长率为 6.3%。结节性痒疹的治疗着重于缓解剧烈搔痒、缩小结节性病变和改善生活品质。治疗通常包括局部治疗（例如皮质类固醇和止痒膏）、全身生物製药（例如度普利尤单抗））和照光治疗。皮肤科医生根据严重程度和潜在疾病制定治疗计划。对患者进行避免抓挠和维持正确护肤的教育至关重要。定期后续观察有助于后续观察并调整治疗方法，以长期控制症状并促进皮肤癒合。

结节性痒疹的盛行率和诊断率不断上升

结节性痒疹的盛行率不断上升，尤其是在患有慢性皮肤病和全身性疾病的人群中，是该疾病的主要成长动力。医疗保健提供者和患者意识的提高，使得诊断能够更早、更准确。皮肤科诊疗和治疗方法工具的普及也进一步推动了这一趋势。随着疾病负担的加重，对有效治疗方法的需求也随之增长，尤其是那些针对潜在免疫机製而非仅仅治疗症状的治疗。

最先进治疗价格高昂，新兴市场获得治疗的机会有限

儘管生物製药和标靶治疗取得了令人鼓舞的进展，但这些治疗方法高成本仍然是一个重大障碍。在开发中地区，有限的报销框架和不均衡的医疗基础设施限制了患者获得治疗的机会。此外，医生培训和对新治疗方法认知的差距也阻碍了新疗法的推广。总而言之，这些挑战减缓了市场渗透，并限制了创新解决方案的普及。

增加对生物目标和小分子疗法的研发投入

製药公司正致力于开发能够打破搔痒-抓痒循环并调节免疫反应的生物製药和小分子药物。突破性疗法认定等监管支持正在加速临床试验和核准。产学研之间的策略合作也正在拓展治疗药物研发线。这些努力有望带来更安全、更有效的治疗方法，并拓宽市场基础。

新疗法的限制性报销政策

儘管像杜匹鲁单抗和奈莫利珠单抗这样的生物製药表现出了强大的疗效，但它们的推广应用却受到严格的报销政策的限制，尤其是在北美和西欧以外的地区。由于成本高且长期数据有限，付款方仍持谨慎态度。这种经济不确定性可能会阻碍生物製剂的广泛应用并减缓创新。如果医保覆盖范围不扩大，许多患者可能会继续依赖疗效较差的传统疗法。

COVID-19的影响：

疫情对结节性痒疹治疗市场产生了双重影响。一方面，供应链中断和皮肤科就诊人数减少暂时减缓了治疗的普及。另一方面，人们对慢性病的认识提高以及远距皮肤科的普及促进了远距会诊和护理的连续性。这场危机也加速了数位医疗的普及，使疾病监测和病患参与度得到改善，最终促进了市场的復苏和成长。

预计系统性治疗领域将成为预测期内最大的领域

预计系统性治疗领域将在预测期内占据最大市场占有率，这得益于其在重症和难治性病例中的卓越疗效。这些治疗方法优于局部用药，因为它们透过针对发炎途径提供长期缓解。核准生技药品的日益普及以及正在进行的新型药物临床试验正在推动该市场的发展。

预计预测期内慢性结节性痒疹的复合年增长率最高。

慢性结节性痒疹预计将在预测期内达到最高成长率。慢性结节性痒疹的特征是持续性搔痒和抗治疗性的结节，需要先进的治疗方法。此疾病的致残性促使患者寻求长期治疗方案，从而推动了对生物製药和免疫调节剂的需求。诊断和认知的提高进一步推动了市场成长。

占比最大的地区：

由于皮肤病患病率上升、医疗基础设施不断扩展以及生物製药可近性的不断提高，预计亚太地区将在预测期内占据最大的市场占有率。中国、印度和日本等国家正在推动皮肤病学现代化，并加大对临床研究的投资，以提高治疗效果。政府为促进皮肤健康和早期诊断的措施也为该地区的主导地位做出了贡献。

复合年增长率最高的地区：

在预测期内，北美预计将呈现最高的复合年增长率，这得益于其先进的医疗基础设施和生物疗法的早期应用。美国在临床研究方面处于领先地位，目前正在进行大量针对IL-31和IL-4/13抑制剂等新型药物的临床试验，从而重塑治疗格局。加拿大虽然在报销政策方面略显保守，但正在透过公共卫生计画和Dupixent等生物製药的监管核准来扩大其可及性。该地区对慢性病管理和数位皮肤病学平台的关注正在推动市场成长。

免费客製化服务

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球结节性痒疹治疗市场（依治疗类型）

  • 局部治疗
    • 皮质类固醇
    • Calcineurin抑制剂
    • 辣椒素乳膏
    • 润肤剂/保湿剂
    • 非处方止痒药
  • 全身性治疗
    • 抗组织胺药
    • 免疫抑制剂
    • 抗惊厥药/神经病变止痛药
    • 抗忧郁症
    • 生物製药
      • IL-4Ra抑制剂
      • IL-31RA拮抗剂
      • JAK抑制剂
      • 其他生物製药
    • 鸦片受体拮抗剂
    • 神经激肽1（NK1）受体拮抗剂
    • 口服类固醇
  • 冷冻疗法
  • 照光治疗
  • 脉衝染料雷射
  • 病灶内注射皮质类固醇
  • 医用胶带/封堵器
  • 其他类型的治疗

6. 全球结节性痒疹治疗市场（依给药途径）

  • 局部的
  • 口服
  • 肠外

7. 全球结节性痒疹治疗市场（依诊断方法）

  • 皮肤切片检查
  • 血液检查
  • 皮肤镜检查
  • 其他诊断方法

8.依结节性痒疹类型分類的全球结节性痒疹治疗市场

  • 慢性结节性痒疹
  • 急性结节性痒疹
  • 亚急性结节性痒疹

9. 全球结节性痒疹治疗市场（依通路）

  • 医院药房
  • 零售药局
  • 网路药局

10. 全球结节性痒疹治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • AbbVie Inc
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Dermavant Sciences
  • Eli Lilly and Company
  • Galderma
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: SMRC30171

According to Stratistics MRC, the Global Prurigo Nodularis Treatment Market is accounted for $2.2 billion in 2025 and is expected to reach $3.4 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Prurigo Nodularis treatment focuses on alleviating intense itching, reducing nodular lesions, and improving quality of life. Management typically involves topical therapies such as corticosteroids and anti-itch creams, systemic medications like immunomodulators or biologics (e.g., dupilumab), and phototherapy. Dermatologists tailor treatment plans based on severity and underlying conditions. Patient education on avoiding scratching and maintaining proper skin care is essential. Regular follow-ups help monitor progress and adjust therapies, aiming for long-term symptom control and skin healing.

Market Dynamics:

Driver:

Rising prevalence and increased diagnosis rates of prurigo nodularis

The increasing incidence of prurigo nodularis, particularly among individuals with chronic dermatological and systemic conditions, is a major growth driver. Enhanced awareness among healthcare providers and patients has led to earlier and more accurate diagnoses. This trend is further supported by improved access to dermatology consultations and diagnostic tools. As the disease burden grows, so does the demand for effective therapies, especially those targeting the underlying immunological mechanisms rather than just symptomatic relief.

Restraint:

High cost of advanced therapies and limited access in emerging markets

Despite promising developments in biologics and targeted treatments, the high cost of these therapies remains a significant barrier. In developing regions, limited reimbursement frameworks and uneven healthcare infrastructure restrict patient access. Additionally, gaps in physician training and awareness about newer treatment modalities further hinder adoption. These challenges collectively slow market penetration and limit the reach of innovative solutions.

Opportunity:

Increasing investment in R&D for targeted biological and small molecule therapies

Pharmaceutical companies are intensifying their focus on developing biologics and small molecule drugs that disrupt the itch-scratch cycle and modulate immune responses. Regulatory support, such as breakthrough therapy designations, is accelerating clinical trials and approvals. Strategic collaborations between industry and academia are also expanding the therapeutic pipeline. These efforts are expected to yield safer, more effective treatments and broaden the market's scope.

Threat:

Limited reimbursement policies for novel therapies

While biologics like dupilumab and nemolizumab show strong efficacy, their adoption is constrained by restrictive reimbursement policies, especially outside North America and Western Europe. Payers remain cautious due to high costs and limited long-term data. This financial uncertainty discourages widespread use and may slow innovation. Without broader insurance coverage, many patients may continue relying on less effective conventional treatments.

Covid-19 Impact:

The pandemic had a dual impact on the prurigo nodularis treatment market. On one hand, supply chain disruptions and reduced dermatology visits temporarily slowed treatment uptake. On the other, heightened awareness of chronic conditions and the expansion of teledermatology encouraged remote consultations and continuity of care. The crisis also accelerated digital health adoption, enabling better disease monitoring and patient engagement, which ultimately supported market recovery and growth

The systemic treatments segment is expected to be the largest during the forecast period

The systemic treatments segment is expected to account for the largest market share during the forecast period due to their superior efficacy in managing severe and refractory cases. These treatments offer long-term relief by targeting inflammatory pathways, making them preferable over topical agents. The growing availability of approved biologics and ongoing clinical trials for novel agents are reinforcing this markets leadership boosting its presence.

The chronic nodular prurigo segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the chronic nodular prurigo segment is predicted to witness the highest growth rate. Chronic nodular prurigo, characterized by persistent, treatment-resistant itch and nodules, demands advanced therapeutic approaches. The debilitating nature of the condition drives patients to seek long-term solutions, boosting demand for biologics and immune modulators. Increased diagnosis and awareness are further fueling the growth of the market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share attributed to rising dermatological disease prevalence, expanding healthcare infrastructure, and growing access to biologic therapies. Countries like China, India, and Japan are investing in dermatology modernization and clinical research, enhancing treatment availability. Government initiatives promoting skin health and early diagnosis are also contributing to regional dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by its advanced healthcare infrastructure and early adoption of biologic therapies. The United States leads in clinical research, with a high volume of ongoing trials for novel agents such as IL-31 and IL-4/13 inhibitors, which are reshaping the therapeutic landscape. Canada, while slightly more conservative in reimbursement policies, is expanding access through public health initiatives and regulatory approvals for biologics like Dupixent. The region's emphasis on chronic disease management and digital dermatology platforms is accelerating market growth.

Key players in the market

Some of the key players in Prurigo Nodularis Treatment Market include AbbVie Inc, Amgen Inc, AstraZeneca, Bayer AG, Dermavant Sciences, Eli Lilly and Company, Galderma, GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson Services, Inc, Leo Pharma, Merck & Co., Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals, Inc, Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, and UCB S.A.

Key Developments:

In June 2025, AbbVie revealed its intention to acquire Capstan Therapeutics to bolster its immunology portfolio, marking another strategic move into next-generation therapies. The deal reflects AbbVie's ongoing commitment to expanding its presence in autoimmune and inflammatory diseases.

In May 2025, Regeneron agreed to acquire genetic testing company 23andMe following its bankruptcy filing, securing its personal genome service and health-research assets. The deal set to close in Q3 2025 retains all staff and establishes an independent privacy ombudsman to oversee consumer data protections

In April 2025, Regeneron announced a long-term partnership worth over $3 billion with Fujifilm Diosynth Biotechnologies to nearly double its biologics production capacity at Holly Springs, NC, and expand manufacturing footprint nationwide.

Treatment Types Covered:

  • Topical Treatments
  • Systemic Treatments
  • Cryotherapy
  • Phototherapy
  • Pulsed Dye Laser
  • Intralesional Corticosteroid Injections
  • Medical Tape/Occlusion
  • Other Treatment Types

Route of Administrations Covered:

  • Topical
  • Oral
  • Parenteral

Diagnosis Methods Covered:

  • Skin Biopsy
  • Blood Tests
  • Dermoscopy
  • Other Diagnosis Methods

Type of Nodular Prurigos Covered:

  • Chronic Nodular Prurigo
  • Acute Nodular Prurigo
  • Subacute Nodular Prurigo

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prurigo Nodularis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Topical Treatments
    • 5.2.1 Corticosteroids
    • 5.2.2 Calcineurin Inhibitors
    • 5.2.3 Capsaicin Cream
    • 5.2.4 Emollients/Moisturizers
    • 5.2.5 Non-prescription Itch Relief
  • 5.3 Systemic Treatments
    • 5.3.1 Antihistamines
    • 5.3.2 Immunosuppressants
    • 5.3.3 Anticonvulsants/Neuropathic Pain Medications
    • 5.3.4 Antidepressants
    • 5.3.5 Biologics
      • 5.3.5.1 IL-4Ra inhibitors
      • 5.3.5.2 IL-31RA antagonists
      • 5.3.5.3 JAK Inhibitors
      • 5.3.5.4 Other Biologics
    • 5.3.6 Opioid Receptor Antagonists
    • 5.3.7 Neurokinin 1 (NK1) Receptor Antagonists
    • 5.3.8 Oral Corticosteroids
  • 5.4 Cryotherapy
  • 5.5 Phototherapy
  • 5.6 Pulsed Dye Laser
  • 5.7 Intralesional Corticosteroid Injections
  • 5.8 Medical Tape/Occlusion
  • 5.9 Other Treatment Types

6 Global Prurigo Nodularis Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Topical
  • 6.3 Oral
  • 6.4 Parenteral

7 Global Prurigo Nodularis Treatment Market, By Diagnosis Method

  • 7.1 Introduction
  • 7.2 Skin Biopsy
  • 7.3 Blood Tests
  • 7.4 Dermoscopy
  • 7.5 Other Diagnosis Methods

8 Global Prurigo Nodularis Treatment Market, By Type of Nodular Prurigo

  • 8.1 Introduction
  • 8.2 Chronic Nodular Prurigo
  • 8.3 Acute Nodular Prurigo
  • 8.4 Subacute Nodular Prurigo

9 Global Prurigo Nodularis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Prurigo Nodularis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc
  • 12.2 Amgen Inc.
  • 12.3 AstraZeneca
  • 12.4 Bayer AG
  • 12.5 Dermavant Sciences
  • 12.6 Eli Lilly and Company
  • 12.7 Galderma
  • 12.8 GlaxoSmithKline plc
  • 12.9 Incyte Corporation
  • 12.10 Johnson & Johnson Services, Inc.
  • 12.11 Leo Pharma
  • 12.12 Merck & Co., Inc.
  • 12.13 Novartis AG
  • 12.14 Pfizer Inc.
  • 12.15 Regeneron Pharmaceuticals, Inc.
  • 12.16 Sanofi
  • 12.17 Takeda Pharmaceutical Company Limited
  • 12.18 Teva Pharmaceutical Industries Ltd.
  • 12.19 UCB S.A.

List of Tables

  • Table 1 Global Prurigo Nodularis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Prurigo Nodularis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Prurigo Nodularis Treatment Market Outlook, By Topical Treatments (2024-2032) ($MN)
  • Table 4 Global Prurigo Nodularis Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 5 Global Prurigo Nodularis Treatment Market Outlook, By Calcineurin Inhibitors (2024-2032) ($MN)
  • Table 6 Global Prurigo Nodularis Treatment Market Outlook, By Capsaicin Cream (2024-2032) ($MN)
  • Table 7 Global Prurigo Nodularis Treatment Market Outlook, By Emollients/Moisturizers (2024-2032) ($MN)
  • Table 8 Global Prurigo Nodularis Treatment Market Outlook, By Non-prescription Itch Relief (2024-2032) ($MN)
  • Table 9 Global Prurigo Nodularis Treatment Market Outlook, By Systemic Treatments (2024-2032) ($MN)
  • Table 10 Global Prurigo Nodularis Treatment Market Outlook, By Antihistamines (2024-2032) ($MN)
  • Table 11 Global Prurigo Nodularis Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 12 Global Prurigo Nodularis Treatment Market Outlook, By Anticonvulsants/Neuropathic Pain Medications (2024-2032) ($MN)
  • Table 13 Global Prurigo Nodularis Treatment Market Outlook, By Antidepressants (2024-2032) ($MN)
  • Table 14 Global Prurigo Nodularis Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 15 Global Prurigo Nodularis Treatment Market Outlook, By IL-4Ra inhibitors (2024-2032) ($MN)
  • Table 16 Global Prurigo Nodularis Treatment Market Outlook, By IL-31RA antagonists (2024-2032) ($MN)
  • Table 17 Global Prurigo Nodularis Treatment Market Outlook, By JAK Inhibitors (2024-2032) ($MN)
  • Table 18 Global Prurigo Nodularis Treatment Market Outlook, By Other Biologics (2024-2032) ($MN)
  • Table 19 Global Prurigo Nodularis Treatment Market Outlook, By Opioid Receptor Antagonists (2024-2032) ($MN)
  • Table 20 Global Prurigo Nodularis Treatment Market Outlook, By Neurokinin 1 (NK1) Receptor Antagonists (2024-2032) ($MN)
  • Table 21 Global Prurigo Nodularis Treatment Market Outlook, By Oral Corticosteroids (2024-2032) ($MN)
  • Table 22 Global Prurigo Nodularis Treatment Market Outlook, By Cryotherapy (2024-2032) ($MN)
  • Table 23 Global Prurigo Nodularis Treatment Market Outlook, By Phototherapy (2024-2032) ($MN)
  • Table 24 Global Prurigo Nodularis Treatment Market Outlook, By Pulsed Dye Laser (2024-2032) ($MN)
  • Table 25 Global Prurigo Nodularis Treatment Market Outlook, By Intralesional Corticosteroid Injections (2024-2032) ($MN)
  • Table 26 Global Prurigo Nodularis Treatment Market Outlook, By Medical Tape/Occlusion (2024-2032) ($MN)
  • Table 27 Global Prurigo Nodularis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 28 Global Prurigo Nodularis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 29 Global Prurigo Nodularis Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 30 Global Prurigo Nodularis Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 31 Global Prurigo Nodularis Treatment Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 32 Global Prurigo Nodularis Treatment Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 33 Global Prurigo Nodularis Treatment Market Outlook, By Skin Biopsy (2024-2032) ($MN)
  • Table 34 Global Prurigo Nodularis Treatment Market Outlook, By Blood Tests (2024-2032) ($MN)
  • Table 35 Global Prurigo Nodularis Treatment Market Outlook, By Dermoscopy (2024-2032) ($MN)
  • Table 36 Global Prurigo Nodularis Treatment Market Outlook, By Other Diagnosis Methods (2024-2032) ($MN)
  • Table 37 Global Prurigo Nodularis Treatment Market Outlook, By Type of Nodular Prurigo (2024-2032) ($MN)
  • Table 38 Global Prurigo Nodularis Treatment Market Outlook, By Chronic Nodular Prurigo (2024-2032) ($MN)
  • Table 39 Global Prurigo Nodularis Treatment Market Outlook, By Acute Nodular Prurigo (2024-2032) ($MN)
  • Table 40 Global Prurigo Nodularis Treatment Market Outlook, By Subacute Nodular Prurigo (2024-2032) ($MN)
  • Table 41 Global Prurigo Nodularis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 42 Global Prurigo Nodularis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 43 Global Prurigo Nodularis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 44 Global Prurigo Nodularis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.